351 related articles for article (PubMed ID: 16639012)
1. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
[TBL] [Abstract][Full Text] [Related]
4. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
5. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
Xu H; Rizzo LV; Silver PB; Caspi RR
Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
[TBL] [Abstract][Full Text] [Related]
6. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
7. Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype.
Silver PB; Rizzo LV; Chan CC; Donoso LA; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1995 Apr; 36(5):946-54. PubMed ID: 7706044
[TBL] [Abstract][Full Text] [Related]
8. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
9. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
10. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
11. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.
Caspi RR; Roberge FG; Chan CC; Wiggert B; Chader GJ; Rozenszajn LA; Lando Z; Nussenblatt RB
J Immunol; 1988 Mar; 140(5):1490-5. PubMed ID: 3346541
[TBL] [Abstract][Full Text] [Related]
12. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens.
Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR
J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
14. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice.
Avichezer D; Chan CC; Silver PB; Wiggert B; Caspi RR
Exp Eye Res; 2000 Aug; 71(2):111-8. PubMed ID: 10930316
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice.
Rizzo LV; Silver P; Wiggert B; Hakim F; Gazzinelli RT; Chan CC; Caspi RR
J Immunol; 1996 Feb; 156(4):1654-60. PubMed ID: 8568272
[TBL] [Abstract][Full Text] [Related]
16. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
19. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.
MartÃn AP; de Moraes LV; Tadokoro CE; Commodaro AG; Urrets-Zavalia E; Rabinovich GA; Urrets-Zavalia J; Rizzo LV; Serra HM
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2056-63. PubMed ID: 15914623
[TBL] [Abstract][Full Text] [Related]
20. A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis.
Boldison J; Khera TK; Copland DA; Stimpson ML; Crawford GL; Dick AD; Nicholson LB
Immunology; 2015 Oct; 146(2):301-11. PubMed ID: 26152845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
